Form 4 for ALZN Alzamend Neuro, Inc.
Accepted 2026-08-31 06:05:03 ET · period of report 2026-08-26 · accession 0001214659-26-011121 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-08-31 06:05 | 2026-08-26 | ALZN | AULT MILTON C III | Dir | S - Sale | $1.56 | -2,000 | 0 | -100% | -$3,116 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-08-26 | S | D | 2,000 | $1.56 | 0 | D | — | — | (F1) The sale of these shares is a matchable transaction subject to Section 16(b) of the Securities Exchange Act of 1934. The reporting person has calculated a short-swing profit in connection with such matchable transactions, which the reporting person intends to disgorge to the Issuer. (F2) The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sale price of $1.5581. The range of sale prices on the transaction date was $1.55 to $1.5619 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price. |